Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis

E. Campello¹ M.W. Henderson² D.F. Noubouossie² P. Simioni¹ N.S. Key²

¹Thrombotic and Hemorrhagic Disease Unit, Department of Medicine, University of Padova, Padova, Italy
²Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Address for correspondence: Nigel S. Key, MB, ChB, FRCP, Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, 1079 Genetic Medicine Building, CB #7035, 120 Mason Farm Road, Chapel Hill, NC 27599, United States (e-mail: nigel_key@med.unc.edu).


Introduction

Patients with cancer are at increased risk to develop venous thromboembolism (VTE), an association that is commonly known as Trousseau’s syndrome.¹² The clinical manifestations of cancer-associated VTE include deep vein thrombosis and pulmonary embolism, as well as visceral or splanchnic vein thrombosis.³ Indeed, cancer is one of the best-established risk factors for VTE.⁴⁻⁵ It has been estimated that ~20% of all first VTE events are associated with cancer.⁵ According to a recent U.K. cohort study that included 6,592 cancer-associated VTEs, the incidence rate of first VTE in patients with active cancer was 5.8 (95% confidence interval [CI], 5.7–6.0) per 100 person-years and the overall incidence rate for recurrence was 9.6 (95% CI, 8.8–10.4) per 100 person-years.⁶ Finally, cancer-associated thrombosis is linked with a worse prognosis, and thromboembolism is the second leading cause of death in cancer.⁵

Several risk factors for VTE usually coexist in cancer patients. These may include certain comorbidities, surgery,
immobility, tumour histology and stage, the presence of indwelling central venous catheters and chemotherapy and/or some molecular targeted therapies. These risk factors, which may be classified as patient-, tumour- or treatment-related, may additively exceed the threshold for clinically overt thrombosis (Fig. 1).

Tissue factor (TF) is the physiologic activator of coagulation in vivo. We and others have reported elevated levels of TF in the circulation of animal models and in patients with cancer. However, although circulating levels of TF correlate with mortality, it does not always correlate with markers of systemic hypercoagulability, or the occurrence of thrombosis. This suggests that other pathways modulate thrombogenesis in cancer. This review will focus on the hypercoagulable state in cancer with particular reference to recent findings concerning the potential contribution of the contact system (CS) of coagulation.

The Contact System

FXII-Dependent Contact Activation

The CS refers to a proteolytic pathway consisting of the zymogens factor XII (FXII) and prekallikrein (PK), and the non-enzymatic cofactor, high molecular weight kininogen (HK). Some definitions also include zymogen FXI. All component proteins are synthesized and secreted by the liver. Contact of plasma with negatively charged surfaces induces a conformational change in zymogen FXII resulting in a small amount of auto-activated FXII (FXIIa;α-FXIIa), which, in turn, cleaves PK to generate kallikrein (KAL). The conformational change in FXII, together with reciprocal activation of FXII by formed KAL and HK, leads to further formation of FXIIa. The activation of FXII and PK generates a potent activation feedback loop that overcomes inactivation of these enzymes by the principal CS inhibitor, the serpin C1 esterase inhibitor (C1INH). The end result of FXIIa generation may be activated FX (FXa) and/or vasoactive and pro-inflammatory kinins, such as bradykinin (BK). FXIa initiates a series of Ca²⁺-dependent proteolytic events that lead to thrombin generation, and production of a fibrin clot. Following the initial generation of thrombin (by whatever mechanism), a powerful amplification mechanism accelerates thrombin formation in a FXI-dependent manner. Additionally, α-FXIIa can be further cleaved by KAL to generate β-FXIIa, which retains the ability to activate PK, but not FXI or FXII, and is able to dissociate from the surface (contact phase). C1INH targets both FXIIa and KAL, accounting for ~93% of plasma FXIIa or β-FXIIa inhibition. Furthermore, antithrombin, α₂-macroglobulin and α₂-antiplasmin also inhibit FXIIa to a lesser extent. Apart from glass surfaces, many other negatively charged surfaces or polyamionic molecules, including silica, kaolin, ellagic acid and sulphated polysaccharides, can accelerate contact activation. Certain glycosaminoglycans (GAGs), such as dermatan sulphate, chondroitin sulphate-E and heparin can also initiate contact activation in vitro or in vivo. However, over the past decade, intensive research efforts have focused on endogenous ‘natural activators’ of the CS. Several damage-associated molecular entities have been suggested to directly drive CS activation during vascular injury and infection including extracellular nucleic acids, misfolded aggregated proteins, mast cell heparin and pathogen-related molecules, such as endotoxin. Additionally, inorganic polyphosphate (polyP), a linear polymer of orthophosphates that is present in many infectious microorganisms and is also secreted by mast cells and platelets, has received the most attention. PolyP accelerates blood clotting and slows fibrinolysis, in a manner that is highly dependent on polymer length. Very long-chain polyP (found in many bacteria) is an especially potent trigger of the contact pathway, but aggregated shorter chain polyP in the form of Ca²⁺-dependent nanoparticles may also activate FXII. Recently, it was demonstrated that membrane-associated platelet polyphosphate condensed into insoluble spherical nanoparticles on the surface of activated platelets potently activates factor XII. Finally, extravascular matrix proteins such as laminin and collagen are capable of assembling and activating the CS to drive coagulation under flow conditions.

The FXII-Independent Activation Pathway

An alternate activation mechanism of the CS, independent of FXII, but involving Zn²⁺- and HK-dependent PK activation on endothelial cells, has been described. It has been observed that...
KAL activity is generated in FXII-deficient, but not in PK-deficient plasma when HK-PK complexes assemble on the surface of endothelial cells, and HK serves as both the binding site and cofactor for PK activation. In this model, a limited amount of KAL is generated in a FXII-independent manner and is subsequently amplified in a FXII-dependent manner. Moreover, KAL generated on the cell surface then cleaves HK, liberating itself from the complex with HK (its substrate) and thereby generating BK. Disinformation from the FXII-dependent pathway, the alternative pathway, and the membrane-mediated activation, apart from endothelial cells, the surfaces of some exogenous microorganisms can also assemble and activate the KAL/kinin system (e.g. the surface of Gram-negative bacteria).38

38 Campello et al.

Fig. 2 Inhibitors of the contact system in plasma. The relative contributions of inhibitors of factors Xla (FXIIa), Xla (FXIIa) and kallikrein (KAL) in plasma (in the absence of heparin) is illustrated. FXIIa is predominantly complexed with C1 inhibitor, which typically accounts for > 90% of inhibition.20 FXIIa is inhibited by α1-antitrypsin (~39%), C1 inhibitor (28%), α2-antiplasmin (28%) and anti-thrombin (5%). However, the addition of heparin greatly increases the contribution of antithrombin in FXIIa inactivation (~35% of complexes).21 C1 inhibitor (55%) and α2-macroglobulin (37%) are the primary inhibitors of KAL, though they have been demonstrated to have different inhibitory rates as well as different clearance rates.22–24

Measuring Activation of the Contact System in Plasma

Investigation of CS activity can be broadly defined as methods that address the potential for exogenous activation, and those that focus on analysis of in vivo activation. Tools such as clotting assays or substrate cleavage can be used to assess a patient’s capacity for CS activation using known initiators, as well as discovery of novel putative physiological activators. Evidence for in vivo activation is predominantly assessed via enzyme-linked immunosorbent assay (ELISA), though Western blot and mass spectrometry have seen specialized use. The most common criticisms applied to these assays are the short half-life of the complexes and the potential for ex vivo activation during collection. Minimization of pre-analytical activation through use of benzamidines or specific CS inhibitors with blood collection is critical and should be considered in study design, since FXII may be rapidly activated ex vivo by contact with blood drawing equipment.40,41 To our knowledge, there are currently no clinically standardized assays to quantify in vivo activation of the CS, presenting an unmet need in cancer-associated thrombosis research.

38 Campello et al.
trypsin inhibitor (CTI) or soybean trypsin inhibitor (STI) may be added to sodium citrate before blood collection to inhibit FXIIa or KAL, respectively.\textsuperscript{45,46} Similarly, ethylenediaminetetraacetic acid (EDTA) will chelate zinc,\textsuperscript{47} a required cation in the contact pathway,\textsuperscript{48} and thus collection of samples in citrate is preferred.

**ELISA**
One of the earliest reports identifying the role of the CS in cancer used capture ELISA to quantify CS proteins in a cohort of gastrointestinal cancer patients.\textsuperscript{49} Depending on the targeted epitopes, these assays may not be able to distinguish between zymogen, enzyme or inhibited protein. However, combining this approach with evidence of reduced zymogen activity indicates prior CS activation. ELISAs able to distinguish activation states offer a greater benefit when analysing clinical samples. Originally developed as radioimmunoassays,\textsuperscript{50} these assays have been modified to ELISA formats that detect CS proteins bound to their physiologic inhibitors including C1-inhibitor esterase (C1INH), $\alpha_1$-antitrypsin, antithrombin, $\alpha_2$-antiplasmin and $\alpha_2$-macroglobulin (\textsuperscript{–}Fig. 2). ELISAs for enzyme-inhibitor complexes have been used in various disease states, although not in the setting of cancer-associated thrombosis, to our knowledge (\textsuperscript{–}Fig. 2).\textsuperscript{51} Certain reports concluded that circulating complexes do not correlate with disease activity, because of their short half-life.\textsuperscript{52} However, the half-lives of these complexes are estimated in the range of 30 to 50 minutes,\textsuperscript{53} which can still detect chronic CS activation. By analogy, thrombin-antithrombin (TAT) complexes have a half-life of ~15 minutes in plasma, yet are an accepted biomarker of on-going coagulation activation in vivo.\textsuperscript{54} Indeed, investigations in patients with endotoxaemia, myocardial infarction and amyloidosis have revealed measurable changes in contact activation using CS enzyme-inhibitor complexes.\textsuperscript{59,51,55,56} More recently, heavy chain-only nanobodies specific for FXIIa have been used to distinguish not only between the activation states of FXII, but also between the $\alpha$ and $\beta$ isoforms.\textsuperscript{57} Finally, HK can be cleaved by either FXIIa or KAL to release HK fragments. An ELISA has been developed to detect cleaved HK in plasma as a marker of CS activation (via KAL) due to its longer half-life (~9 hours),\textsuperscript{58} but has yet to be applied to cancer-associated thrombosis research.

**Western Blot**
An alternative approach for detecting activation of the CS activation in plasma is Western blotting. Here, detection of enzyme-inhibitor complexes or cleavage of HK (an indirect measurement of BK release) provide a semi-quantitative measurement of CS activation.\textsuperscript{59} Western blotting can offer advantages such as the speciation of FXIIa ($\alpha$ or $\beta$) when analysed under reducing conditions, or complexes with inhibitors under non-reducing conditions, without using specific monoclonal antibodies or the aforementioned nanobodies.\textsuperscript{60} Detection of heavy chain-only HK by Western blotting has shown sensitivity to concentrations as low as 5 ng/mL,\textsuperscript{61} with discernible differences in the plasma of rodent models of BK-mediated diseases.\textsuperscript{62} However, due to the low throughput of Western blotting, clinical samples are not typically analysed using this approach.

**Mass Spectrometry**
The major inflammatory effector of the CS is BK, a 9 amino acid peptide generated from the cleavage of HK by KAL. Detection of BK versus FXIa (or FXIa-inhibitor complex) provides a potentially valuable measurement of the inflammatory versus procoagulant endpoints of CS activation. Unfortunately, BK has a circulating half-life < 20 seconds\textsuperscript{63} due to its rapid metabolism by angiotensin-converting enzyme I (ACE) in the lungs, which greatly limits its detection when it is generated in vivo. However, mass spectrometry may be used to quantify the major stable metabolite, BK 1–5.\textsuperscript{64} Given the role of BK in tumour progression,\textsuperscript{65,66} and evidence for thrombotic protection in mice deficient in the BK2 receptor,\textsuperscript{64} this underutilized approach should be considered in the evaluation of clinical samples.

**Clinical Evidence of Contact System Activation in Cancer**
As already mentioned, early evidence of CS activation in cancer was presented in 1990.\textsuperscript{49} CS activation was evaluated in 69 patients with gastrointestinal cancer (12 with gastric, 15 with pancreatic and 42 with colon cancer), 33 of who had liver metastases, and in 118 healthy controls recruited from blood donors (\textsuperscript{–}Table 1). Antigen levels of FXII, PK, HK and C1INH were measured by immunohemical assays; activity levels of PK and C1INH were measured by chromogenic assays. Values of FXII, PK, HK and C1INH were expressed as a percentage of human standard plasma pool values. FXII, PK and HK antigens were decreased in patients with gastrointestinal cancer (84 ± 28%, 74 ± 19% and 86 ± 14%, respectively) compared with the control group (94 ± 27%, 88 ± 18% and 98 ± 14%, respectively), but only PK and HK values were statistically different ($p < 0.05$ for both). PK activity was significantly decreased compared with controls (74 ± 21% vs. 101 ± 17%, $p < 0.05$). C1INH antigen and activity were significantly increased in cancer compared with controls ($p < 0.05$ for both comparisons). Interestingly, in the subgroup of patients with metastatic colon cancer, FXII, PK and HK levels were significantly decreased (78 ± 18%, 75 ± 13% and 77 ± 9%, respectively) compared with controls (all $p < 0.05$). C1INH was significantly increased both in patients with and without metastases compared with controls in both the immunological and functional assays ($p < 0.05$). The authors concluded that patients with intestinal cancer manifest reduced contact factor levels with markedly elevated inhibitor levels. Battistelli et al measured plasma activities of fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI and FXII in 73 patients with non-metastatic colorectal cancer (48 colon and 25 rectum) and in 67 matched controls.\textsuperscript{43} They showed that the mean plasma activity of fibrinogen (400 ± 113 mg/dl), FVIII (145 ± 50%), FIX (127 ± 29%) and FV (131 ± 65%) were significantly higher in colorectal cancer patients than in control subjects (287 ± 74 mg/dl, 92 ± 35%, 109 ± 22% and 108 ± 35%, respectively), while FVII (102 ± 25% vs. 118 ± 34%, $p = 0.004$) and FXII (96 ± 26% vs.
113 ± 3%, p = 0.003) levels were significantly decreased. Interestingly, FVII was highly correlated with FXII (p < 0.01) only in cancer patients. The authors concluded that decreased FVII and FXII activity may be indices of intravascular coagulation activation in colorectal cancer. More recently, Pan et al measured CS activation in 10 lung cancer patient plasmas compared with normal pooled plasma. PK, HK and C1INH were quantified by Western blot. The authors concluded that CS activation was present, as evidenced by cleaved C1INH and C1INH/protease complexes in all 10 patients, with absent HK in 9 patients, decreased amounts of PK in 6 and KAL/protease complexes in 5. Moreover, the authors confirmed the same CS activation pattern in 11 colon, 9 breast, 3 pancreatic and 1 renal cancer patients. In particular, all of the pancreatic cancer patient samples showed an absence of detectable HK, whereas only one of the colon cancer plasmas had undetectable HK, and this occurred in a patient with stage IV disease (Table 1).

### Mechanisms of Contact System Activation in Cancer

Although several observations documenting activation of the CS in different cancers have been published, the responsible mechanism(s) is poorly understood. As previously mentioned, the variety of assays that have been used makes it difficult to compare results. Table 2 summarizes the reported mechanisms of CS activation in cancer.

### Microvesicles

Microvesicles (MV) are submicron, lipid bilayer membrane particles, shed by various cells upon activation or apoptosis. Our group and others have described elevated levels of circulating MVs, including exosomes (MV of 50–100 nm in diameter) derived from tumour and host blood cells types in cancer patients. Cancer chemotherapy can potentially induce MV release from tumour, blood or endothelial cells. Red cell and platelet transfusions administered to cancer patients are additional sources of MVs. MVs and exosomes may play a major role in tumourigenesis, tumour progression, metastasis and cancer-associated thrombosis.

As already mentioned, the prothrombotic role of MVs has been mainly ascribed to TF-bearing MVs. However, in a cohort of women with breast cancer, circulating annexin-V positive MVs were elevated and correlated with the stage of the tumour. When analysed according to cellular origin, platelet-derived MVs represented the vast majority (>80%); their level correlated with plasma levels of prothrombin fragment 1.2, suggesting a role in systemic hypercoagulability.

### Table 2: Studies of contact system activation in patients with cancer

<table>
<thead>
<tr>
<th>Patients</th>
<th>Patients/controls</th>
<th>Cancer subtype</th>
<th>Analytes</th>
<th>Main results</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>69 gastric-intestinal cancer (33 with liver metastasis)</td>
<td>69/118</td>
<td>12 gastric 15 pancreatic 42 colon</td>
<td>FXII, PK, HK, C1INH immunological and functional assays</td>
<td>1. FXII, PK and HK activity decreased 2. C1INH increased 3. CS activation more pronounced in patients with liver metastasis</td>
<td>49</td>
</tr>
<tr>
<td>73 colorectal cancer without metastasis</td>
<td>73/67</td>
<td>48 colon 25 rectum</td>
<td>Fibrinogen, FII, FV, FVII, FVIII, FIX, FX, FXI, FXII activity</td>
<td>1. FVII and FXII activity decreased 2. FVII highly correlated with FXII</td>
<td>43</td>
</tr>
<tr>
<td>34 cancer (11 advanced disease)</td>
<td>34/NPP</td>
<td>10 lung 11 colon 9 breast 3 pancreatic 1 renal</td>
<td>PK, KAL/protease complexes, HK, C1INH and C1INH/protease complexes by Western analysis</td>
<td>1. Cleaved C1INH and C1INH/protease complexes, absence of HK, decreased amounts of PK, and KAL/protease complexes (primarily in lung cancer patients) 2. Thrombin generation correlated with KAL/protease complexes</td>
<td>67</td>
</tr>
<tr>
<td>20 prostate cancer</td>
<td>20/20</td>
<td>20 prostate</td>
<td>FXIIa activity, thrombin generation</td>
<td>Humanized antibody 3F7 inhibited FXIIa activity and reduced thrombin generation in normal plasma samples spiked with prostates from pancreatic cancer patients</td>
<td>44</td>
</tr>
</tbody>
</table>

Abbreviations: C1INH, C1esterase inhibitor; FXII, factor XII; HK, high molecular weight kininogen; KAL, kallikrein; NPP, normal pool plasma; PK, prekallikrein; TF, tissue factor.
tumours, although the correlation with prothrombin fragment was seen only in patients with metastatic cancer. Red blood cell and platelet-derived MVs have previously been shown to activate coagulation through the contact pathway in the context of blood product storage and human endotoxaemia, although here again, the precise molecular trigger for this event remains to be determined. In addition to blood cell-derived MVs, certain tumour-derived exosomes have also been shown to interact with the CS. Exosomes spontaneously released or induced by treatment of the B16 melanoma cell line with doxorubicin in vitro, triggered thrombin and fibrin generation in plasma in the presence of inhibitory TF antibodies. In a mouse model of breast cancer, tumour-derived exosomes cooperated with neutrophils primed by tumour-derived G-CSF to generate NETs and enhance thrombosis (further discussed below). Additionally, exosomes secreted by prostate cancer cells (prostasomes) trigger thrombin generation in vitro in a dose-dependent manner, and induce lethal pulmonary embolism in mice. Moreover, the addition of a recombinant FXIIa inhibitor significantly reduced peak and total thrombin generated by prostasomes, and the combined application of FXIIa and TF inhibitors completely blunted thrombin generation. Polyphosphates were found on the surface of prostasomes. Treatment of prostasomes with specific inhibitors of polyphosphates or with polyphosphate degrading enzymes abrogated prostasome-induced FXIIa generation in vitro and protected mice from prostasome-induced lethal pulmonary embolism. However, since similar effects were also observed following inhibition of TF, both the intrinsic and extrinsic pathways seemed to contribute to thrombosis in this model. Further data are required in a diverse range of cancers to understand the role that circulating exosomes/MVs may play in CS activation.

**Cell-Free DNA, Histones and Neutrophil Extracellular Traps**

Elevated circulating levels of cell-free DNA (cfDNA) and histones, the major molecular components in nucleosomes/chromatin, are found in cancer patients. They are associated with adverse outcomes and are positively correlated with markers of in vivo coagulation activation such as plasma TAT and D-dimer levels. The mechanisms of extracellular release and the cellular origin of cfDNA and

<table>
<thead>
<tr>
<th>Cancer type</th>
<th>Mechanism suggested</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal with or without liver metastasis; no VTE</strong></td>
<td>1. Proteolytic enzymes such as plasmin, collagenase and cathepsin 2. Kallikrein produced by cancer cells 3. Imbalance of CS linked with metastatic process</td>
<td>49</td>
</tr>
<tr>
<td><strong>Colorectal without metastasis; no VTE</strong></td>
<td>Intravascular coagulation activation mediated by both extrinsic and intrinsic pathways</td>
<td>43</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td>1. High levels of MVs 2. Prothrombotic role mainly ascribed to TF-bearing MVs 3. Red blood cell and platelet-derived MVs have been shown to activate CS</td>
<td>69,70,75,76</td>
</tr>
<tr>
<td><strong>Melanoma cell line</strong></td>
<td>Exosomes spontaneously released or induced by treatment with doxorubicin triggered thrombin generation even in the presence of inhibitory TF antibodies</td>
<td>80</td>
</tr>
<tr>
<td><strong>Prostate cancer</strong></td>
<td>1. Prostasomes secreted by prostate cancer cells activated intrinsic pathway via PolyP 2. Blocking FXIIa reduced the prothrombotic potential of prostasomes</td>
<td>44</td>
</tr>
<tr>
<td><strong>Acute myeloid leukaemia</strong></td>
<td>Increased levels of cell-free plasma DNA indicative of contribution of the contact pathway to systemic coagulation activation in the total patient cohort and in patients with lower TF procoagulant activity</td>
<td>85</td>
</tr>
<tr>
<td><strong>Breast cancer</strong></td>
<td>Cell-free DNA released from epirubicin-treated whole blood significantly elevated thrombin generation in a dose-dependent manner via activation of the contact pathway</td>
<td>95</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td>1. Increased plasma H3Cit in active cancer with stroke compared with stroke without cancer 2. H3Cit positively correlated with plasma TAT</td>
<td>102</td>
</tr>
<tr>
<td><strong>Miscellaneous</strong></td>
<td>1. High GAGs (glucosamine and galactosamine) levels expressed by tumoural tissue (mainly lung) or by endothelial cells may activate CS 2. Carcinoma mucins may induce CS activation</td>
<td>67</td>
</tr>
</tbody>
</table>

**Abbreviations**: CS, contact system; F, factor; GAGs, glycosaminoglycans; H3Cit, citrullinated histone H3; MVs, microvesicles; PolyP, polyphosphate; TAT, thrombin-antithrombin complexes; TF, tissue factor; VTE, venous thromboembolism.
histones are unclear, and probably vary according to tumour type, patient co-morbidities and chemotherapy. In cancer patients, cfDNA may be either tumour-derivered or released from apoptotic or necrotic non-tumoural tissues, such as neutrophils.\textsuperscript{86} Cancer chemotherapy is associated with increased plasma levels of cfDNA.\textsuperscript{87–89} Multiple groups, including our own, have reported FXII-dependent procoagulant activity of purified DNA in vitro.\textsuperscript{90–94} Specifically, Swystun et al\textsuperscript{95} showed that cfDNA purified from epirubicin-treated whole blood ex vivo significantly elevated thrombin generation in a dose-dependent manner by a mechanism involving activation of the contact pathway. Purified histones promote platelet activation and aggregation, and trigger thrombin generation in a platelet-dependent manner.\textsuperscript{96,97} They also induce phosphatidylyserine expression on red blood cells and impair thrombomodulin-dependent protein C activation, leading to enhanced thrombin generation in plasma ex vivo.\textsuperscript{98,99} Noteworthily, it is unclear if DNA and histones circulate in their free forms. It is also unknown if DNA or histones bound to other blood components affect their respective procoagulant activities observed in vitro.

Cancer cells secrete various types of cytokines that modify neutrophil biology, leading to changes in neutrophil counts and state of activation, including the release of neutrophil extracellular traps (NETs).\textsuperscript{81,100,101} Animal models have suggested that NETosis plays a major role in cancer-associated thrombosis. In a mouse model of mammary carcinoma, tumour-bearing mice developed a leukaemoid reaction and spontaneous delayed onset thrombosis within the lungs. Interestingly, the percentage of circulating hypercitrullinated neutrophils increased at day 21 post-tumour injection and decreased at the time that thrombosis occurred. Furthermore, the disappearance of hypercitrullinated neutrophils from the circulation coincided with the appearance of hypercitrullinated histone H3 (H3Cit) in the plasma of these mice.\textsuperscript{102} Hypercitrullination of histones, which is believed to be mediated by neutrophil PAD14 enzyme, has been proposed to be a specific marker of NETosis. Hence, the observations in this model were thought to indicate a major role of tumour-induced NETs in cancer-associated thrombosis. In another study, orthotopic injection of the same cancer cell line into mice led to rapid development of metastases. Tumour-bearing mice exhibited a reduced time to jugular vein occlusion during venous thrombosis induced by Rose Bengal/laser photochemical injury compared with control mice, as well as reduction in time to arterial occlusion triggered in the carotid artery by ferric chloride injury. Pre-treatment of mice with DNase 1 abolished the differences between tumour-bearing and control mice during both venous and arterial thrombosis challenges, further suggesting a role of NETs in these models of cancer-associated thrombosis.\textsuperscript{81} In humans, Thålin et al reported a significantly higher level of plasma H3Cit in patients with active cancer and stroke than in patients with stroke without active cancer. In this study, plasma level of H3Cit positively correlated with plasma TAT, supporting a possible link between NETosis and cancer-associated thrombosis.\textsuperscript{102} However, the mechanisms by which NETs promote thrombosis are not fully understood and are likely multifactorial. NETs released intravascularly adhere to the vessel wall, where they resist flow and trap suspended and soluble components of the blood, including those of the clotting system.\textsuperscript{90,96,103,104} In this way, NETs facilitate interactions between coagulation components, enhance thrombin generation and increase thrombus size. These prothrombotic properties can be abrogated by preventing NET formation or by dismantling the NET scaffold, using DNase 1, for example.\textsuperscript{81,104} However, whether the intact NET macromolecular structure directly activates coagulation is controversial. In cancer, MVs, activated leucocytes and/or cancer cells themselves can provide circulating TF, which are trapped on NETs. Neutrophil elastase, an enzyme abundant in neutrophil cytoplasmic granules and in extruded NETs, has been shown to enhance thrombosis by inhibiting TF pathway inhibitor.\textsuperscript{105} Deficiency in FXII does not confer protection from thrombus formation in NET-dependent animal models of thrombosis.\textsuperscript{106} Several studies have reported CS activation using thrombin generation in plateau-poor plasma containing NETs generated ex vivo.\textsuperscript{90,91,107} However, in the presence of intact NETs, we did not observe any thrombin generation in platelet-free plasma, or in a purified CS reconstituted in buffer.\textsuperscript{52}

**Activated Platelets**

There is an extensive literature on the multiple roles of activated platelets in cancer-associated thrombosis.\textsuperscript{108} Activation of the CS by activated platelets has been observed since the early 1980s.\textsuperscript{109} Activated platelets can expose membrane-bound divalent ion-complexed polyphosphate nanoparticles, which resist circulating polyphosphatases and trigger FXII activation.\textsuperscript{31} Released platelet polyphosphates have also been reported to activate the CS in vitro and in vivo.\textsuperscript{28,110} A recent study by Riedl et al demonstrated platelet activation mediated by expression of podoplanin by brain tumours,\textsuperscript{111} likely through CLEC-2 signalling.\textsuperscript{112} However, whether tumour-podoplanin-CLEC-2-mediated platelet axis promotes thrombosis through CS activation has not been evaluated.

**Glycosaminoglycans**

At a molecular level, certain GAG species have been shown to activate FXII and the KAL-kinin pathway, with adverse clinical outcomes; the most notable example was when heparin batches contaminated by hypersulphated chondroitin sulphate moieties were inadvertently administered to patients.\textsuperscript{25} Whether tumour cells can similarly produce atypical GAGs that activate the CS is unclear. Pan et al measured levels of glucosamine- and galactosamine-containing glycans as a putative mechanism for CS activation in cancer patients.\textsuperscript{67} Galactosamine levels were increased in lung cancer but not in breast or pancreatic cancer patients compared with controls; on the other hand, glucosamine levels were increased in both lung and breast cancer patients compared with controls, although this was not observed in pancreatic cancer (►Table 2).
Catheter-Related Thrombosis

The use of venous catheters to facilitate chemotherapy, transfusions, parenteral nutrition and blood sampling is common in cancer patients. Up to 66 and 50% of patients with cancer and indwelling catheters develop insertion site thrombosis or pulmonary embolism, respectively.113,114 Reported risk factors for catheter-related thrombosis (CRT) in cancer patients include left-sided or superior vena cava insertion, chest radiotherapy, metastasis and elevated homocysteine levels.115 The mechanisms by which catheters promote thrombosis are incompletely understood. Vessel injury and stasis caused by catheter insertion, cancer-induced thrombocytopenia, and in certain cancer types treatments are associated with bleeding side effects, which further contribute to thrombosis.115 Additionally, materials used to construct medical devices are inherently procoagulant to a greater or lesser extent. In contrast to the healthy endothelium, which actively resists thrombosis, artificial surfaces promote clotting through a complex series of interconnected processes that include protein adsorption and platelet and leukocyte adhesion and activation that ultimately leads to fibrin formation.116 CS proteins including FXII, PK, HK and FXI adsorb to artificial surfaces,117 and catheter segments shorten clotting times when introduced in re-calculated plasma ex vivo. This procoagulant effect is attenuated in the presence of CTI, and is abolished in FXII- or FXI-deficient plasma, indicating that clotting is mediated by CS activation.118 Furthermore, contact of whole blood with some materials used to manufacture medical devices induces TF expression on monocytes and TF-dependent shortening of clotting time ex vivo.117 Since monocytes adhere to catheter surfaces, it is therefore possible that activation of the extrinsic pathway also contributes to CRT. While the relative contribution of the intrinsic versus the extrinsic pathway is unknown, one can speculate that these two pathways act synergistically to promote CRT, especially in the context of cancer where circulating TF is likely to be present.119,120

Therapeutic Implications of Contact System Activation in Cancer

Current practice recommends the use of heparins for the treatment and prophylaxis of VTE, as well as the treatment of symptomatic CRT in patients with cancer.121 These treatments are associated with bleeding side effects, which can be of major concern in patients with chemotherapy-induced thrombocytopenia, and in certain cancer types associated with a high risk of bleeding. The use of anticoagulation for routine prophylaxis of CRT is not recommended, as it largely fails to prevent CRT occurrence.115 Additionally, manufacturing catheters using biomaterials that are less thrombogenic would help to further reduce the incidence of CRT. Indeed, coating catheters with polyethylene glycol and CTI reduced protein adhesion, the ability to trigger FXII-dependent coagulation activation in plasma and a 2.5-fold prolongation of time to occlusion when inserted in the jugular vein of rabbits.119,122 Other coating compounds, including heparins, direct thrombin inhibitors and thrombomodulin, have shown promising results in reducing the thrombogenicity of materials used to make medical devices in vitro, though available data in vivo are limited.116 Interestingly, it seems that anticoagulant agents that target serine proteases of the common pathway (FXa and thrombin) have limited capacity to prevent medical device-induced thrombosis in vivo and ex vivo.118,123 It has been postulated that medical device-driven CS activation generates FXa and thrombin in concentrations that overcome the inhibition by therapeutic doses of FXa and thrombin inhibitors.116 Using agents that inhibit CS activation might provide more efficient anticoagulation. However, further studies are required to evaluate the use of CS inhibitors for the prevention of medical device-induced thrombosis in clinical settings.

Although more evidence from basic, translational and clinical research is required, the potential contribution of CS activation in non-CRT thrombosis in cancer opens the door to novel therapeutic possibilities. Inhibition of the CS may protect against thrombosis without increasing the risk of bleeding, as previously shown by genetic or pharmacologic inhibition of FXIIa in animals.124 Several classes of CS inhibitors are under development as thromboprotective and/or anti-inflammatory agents.125–147 (Table 3). Most of these agents have shown ability to inhibit CS in vitro or in experimental models of thrombosis in animals without cancer. Conceptually, targeting FXII or FXIIa would be reasonable in settings where CS activation is the dominant mechanism of coagulation activation. As mentioned above, circulating TF is present in many cancers. TF is very efficient at initiating coagulation, but is also efficiently inhibited by TFPI.148 Thrombus formation then relies on the contribution of the intrinsic pathway for subsequent thrombin generation. This can be achieved by FXIIa formation that will then activate FXI, or by the feedback activation of FXI by thrombin. Consequently, FXI or FXIIa are good targets to interrupt the additive or synergistic effects of activation of both the extrinsic and intrinsic pathways. Moreover, such an approach seems to represent a reasonable compromise between preventing thrombosis with a lower risk of bleeding compared with commonly used heparins. For instance, reducing plasma FXI to 20% of normal levels using an antisense oligonucleotide (ASO ISIS-416858) was more effective than low molecular weight heparin in preventing VTE following knee replacement surgery, without any increase in intraoperative or postoperative bleeding.126,143,144 To date, no clinical trial has evaluated therapies targeting FXI/XIIa to prevent thrombosis in the context of cancer.

Systemic administration of DNase confers protection against experimental models of cancer-associated thrombosis.81 Thus, DNase I represents a potential candidate for the prevention or treatment of thrombosis, as it does not directly affect haemostasis. However, convincing evidence supporting the contribution of NETs to human thrombosis, and clinical experience with systemic administration of DNase I in humans are lacking, although recombinant DNase I aerosol is used in humans with cystic fibrosis.147
<table>
<thead>
<tr>
<th>Inhibitor class</th>
<th>Mechanism of action</th>
<th>Evidence</th>
<th>Disadvantages</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Factor XIIa inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corn trypsin inhibitor (CTI)</td>
<td>Kunitz-type reversible inhibitor of the FXIIa active site; purified from corn seeds</td>
<td>1. CTI-coated catheters inhibited FXIIa activity 2. CTI-coated catheters showed longer time to occlusion in a catheter thrombosis model in rabbits</td>
<td>1. Does not fully block contact activation at concentrations typically used (30–100 μg/mL) 2. High concentrations may inhibit also FXIa 3. Expensive</td>
<td>119,127</td>
</tr>
<tr>
<td>Recombinant FXIIa inhibitor rHAT-infestin-4</td>
<td>Highly specific FXIIa inhibitor formed by the IV domain of Kazal-type serine protease inhibitor from the midgut of insect Triatoma infestans + recombinant human albumin</td>
<td>1. Intravenous infusion abolished occlusive arterial thrombus formation in mice and rats 2. Prevented lethal PE, ischaemic stroke, thrombus formation on ruptured atherosclerotic plaques</td>
<td>1. Potentially immunogenic 2. Concentration-dependent inhibition of plasmin and FXa</td>
<td>128,129</td>
</tr>
<tr>
<td>Synthetic peptide H-D-Pro-Phe_Arg-chloromethyl ketone (PCK)</td>
<td>Irreversibly inhibits amidolytic FXIIa activity and KAL-mediated FXII activation</td>
<td>Prevented cerebral infarction in a mouse model</td>
<td>Unknown</td>
<td>130</td>
</tr>
<tr>
<td>Monoclonal antibodies targeting FXIIa/FXIIa 9A2 and 15H8</td>
<td>Monoclonal antibodies against the human FXII heavy chain that interfere with conversion to FXIIa</td>
<td>15H8 reduced fibrin deposition and limited platelet-rich thrombus growth in a collagen-coated thrombogenic graft in baboons</td>
<td>Unknown</td>
<td>131</td>
</tr>
<tr>
<td>Monoclonal antibody targeting FXIIa 3F7</td>
<td>Recombinant fully humanized antibody that binds FXIIa enzymatic pocket with high affinity</td>
<td>1. Abolished thrombus formation under flow in experimental mouse and rabbit models 2. Protected mice from cancer-induced lethal PE 3. Minimal immunogenic potential 4. Long half-life</td>
<td>Unknown</td>
<td>44,132,133</td>
</tr>
<tr>
<td>Antisense oligonucleotide</td>
<td>Reduces FXII hepatic synthesis</td>
<td>1. Reduced arterial and venous thrombosis in mice 2. Attenuated catheter-related thrombosis in rabbits</td>
<td>Slow onset: 3–4 wk of treatment required to lower FXII levels into the therapeutic range</td>
<td>120,126,134</td>
</tr>
<tr>
<td>Factor XIa inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protease nexin-2 Kunitz-domain (PN2KPI) and Desmolaris</td>
<td>Kunitz-type FXIa active site inhibitors</td>
<td>Inhibited arterial thrombosis in mice</td>
<td>Desmolaris also inhibits FXa</td>
<td>135,136</td>
</tr>
<tr>
<td>4-carboxy-2-azetidinone BMS-262084</td>
<td>Irreversible inhibitor of FXIa active site</td>
<td>Inhibited thrombus formation in rabbit arterial and venous thrombosis model</td>
<td>Unknown</td>
<td>137</td>
</tr>
<tr>
<td>Tetrahydroquinoline (THQ) derivatives and Phenylimidazoles</td>
<td>Reversible inhibitor of FXIa active site</td>
<td>Unknown</td>
<td>Unknown</td>
<td>138,139</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Inhibitor class</th>
<th>Mechanism of action</th>
<th>Evidence</th>
<th>Disadvantages</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monoclonal antibody O1A6 (aXIMAb)</td>
<td>Inhibits FXI activation by binding FXI/FXIa Apple3 domain</td>
<td>Limited acute arterial thrombus growth and blood vessel occlusion in a baboon AV shunt model</td>
<td>Unknown</td>
<td>140</td>
</tr>
<tr>
<td>Monoclonal antibody 14E11</td>
<td>Inhibits FXI activation by FXIIa by binding to FXI Apple2 domain</td>
<td>Reduced thrombus formation in baboon vascular graft model and disseminated intravascular coagulation in mouse peritonitis model</td>
<td>Unknown</td>
<td>141,142</td>
</tr>
<tr>
<td>Antisense oligonucleotide IONIS-416858</td>
<td>Complementary to human and rhesus macaque FXI mRNA - reduces FXI hepatic synthesis</td>
<td>300-mg superior to enoxaparin as prophylaxis to prevent VTE in patients undergoing knee replacement (phase 2 randomized trial) with comparable bleeding</td>
<td>Slow onset: 3–4 wk of treatment required to lower FXI levels into the therapeutic range</td>
<td>143,144</td>
</tr>
<tr>
<td>Other inhibitors</td>
<td>Polycationic compounds</td>
<td>Multifunctional cationic groups in the core of a dendritic polymer; positive charges responsible for binding and inhibition of polyP</td>
<td>1. Thromboprotective in mouse models of arterial thrombosis 2. Reduced bleeding compared with heparin 3. Nontoxic</td>
<td>145,146</td>
</tr>
<tr>
<td>DNase</td>
<td>Recombinant human DNase I</td>
<td>Treatment with DNase I abolished thrombus formation in a murine breast cancer model</td>
<td></td>
<td>82,147</td>
</tr>
</tbody>
</table>

Abbreviations: AV, arteriovenous; PE, pulmonary embolism; VTE, venous thromboembolism.
Conclusion

Increasing interest in the contact pathway of coagulation has focused on a possible role in the pathogenesis of thrombosis. Preliminary observations have noted the presence of activation of the CS in gastrointestinal, lung, breast and prostate cancers. However, assays used to measure CS activation differed among studies. A standardized approach that would best quantify in vivo CS activation in clinical samples has yet to be developed. Several candidates that are known to activate the CS in vitro are found in the circulation of patients with cancer. However, further research is needed to establish what biological surfaces or molecular component(s) promote CS activation in human cancer. It is possible that the surface varies with the type of tumour. For instance, polyphosphate-bearing prostasomes seem to be a candidate in prostate cancer. More studies are required to understand if the type, stage, grade and treatment of cancer modulate CS activation. Although NETosis appears to play a role in cancer-associated thrombosis in animals, it remains unclear if this effect is due to direct CS activation. As TF is up-regulated in many cancers, it seems reasonable to propose that concomitant activation of both the intrinsic and extrinsic pathways acts synergistically to produce a highly prothrombotic state in cancer (► Fig. 3). It is tempting to speculate that while TF is the primary initiator, CS activation contributes to the amplification of thrombin generation. Future research should focus primarily on the standardization of methods to measure CS in clinical samples. This advance would further our understanding of the mechanisms by which CS activation contributes to non-CRT in humans. For CRT where CS activation is thought to play a major role, novel

![Molecular activators of coagulation in cancer. Coagulation activation in cancer-associated thrombosis may be explained by contributions from both the tissue factor ('extrinsic') and FXII/FXI-dependent ('intrinsic') pathways. Tissue factor–bearing microvesicles may be released into the circulation by various tumour types and promote thrombin generation and ultimately thrombosis. FXII may be activated in vivo by a variety of negatively charged molecules. These could include phosphatidylserine (e.g. on microvesicles), glycosaminoglycans, polyphosphate, collagen, nucleic acids and misfolded proteins. Activation of the contact system in cancer would promote the generation of thrombin, thereby exacerbating thrombotic risk.](image)
therapeutic options targeting contact pathways should be evaluated in well-designed clinical trials.

Conflict of Interest
None declared.

Acknowledgements
Support from the ISTH Training Fellowship Program (to EC) is gratefully acknowledged. NSK was supported by NIH grant R01-HL095096.

References
12. de Maat S, de Groot PG, Maas C. Contact system activation on endothelial cells. Semin Thromb Hemost 2014;40(08):887–894
26. Tans G, Rosing J, Berrettini M, Lämmle B, Grif...
Minnema MC, Wittekoek ME, Schoonenboom N, Kastelein JJ,
Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten
Konings J, Govers-Riemslag JW, Spronk HM, Waltenberger JL, ten
Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO.
Shibayama Y, Joseph K, Nakazawa Y, Ghebreihiwet B, Peerschke
Nyborg JK, Peersen OB. That zincing feeling: the effects of EDTA
Boknäs N, Faxälv L, Lindahl TL, Ramström S. Contact activation:
Thromb Haemost 2013;110(03):458–452

40 Ramström S. Clotting time analysis of citrated blood samples is
strongly affected by the tube used for blood sampling. Blood
Coagul Fibrinolysis 2005;16(06):447–452
41 Boknäs N, Faxälv L, Lindahl TL, Ramström S. Contact activation:
important to consider when measuring the contribution of
tissue factor-bearing microparticles to thrombin generation
using phospholipid-containing reagents. J Thromb Haemost
42 Weng LC, Cushman M, Pankow JS, et al. A genetic association
study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study. Hum Mol
Genet 2015;24(08):2401–2408
levels in non-metastatic colorectal cancer patients. Int J Biol
Markers 2008;23:36–41
XII pathway drives coagulation in prostate cancer-associated
45 Rajkjaer R, Hasan AA, Motta G, Schousboe I, Schmaier AH. Factor
XII does not initiate prekallikrein activation on endothelial cells.
Thromb Haemost 1998;80(01):74–81
46 Rao GJ, Posner LA, Nadler HL. Deficiency of kallikrein activity
in plasma of patients with cystic fibrosis. Science 1972;177
(4049):610–611
47 Nyborg JK, Peersen OB. That zincing feeling: the effects of EDTA
48 Shibayama Y, Joseph K, Nakazawa Y, Ghebreihiwet B, Peerschke
El, Kaplan AP. Zinc-dependent activation of the plasma kinin-
forming cascade by aggregated beta amyloid protein. Clin Immunol
1999;90(01):89–99
49 Roeie O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO.
Studies on components of the contact phase system in patients
with advanced gastrointestinal cancer. Cancer 1990;65(06):
1355–1359
of the contact system of coagulation in vitro and in vivo:
quantitation of activated Hageman factor-C1-inhibitor and kall-
likein-C1-inhibitor complexes by specific radioimmunoassays.
Thromb Haemost 1987;58(02):778–785
51 Konings J, Govers-Riemslag JW, Spronk HM, Waltenberger JL, ten
Cate H. Activation of the contact system in patients with a first
52 Wullemina WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, ten
Cate H. Inactivation of factor Xa in vivo: studies in chimpanzees
53 Minnema MC, Wittekoek ME, Schoonenboom N, Kastelein JJ,
Hack CE, ten Cate H. Activation of the contact system of coagula-
tion does not contribute to the hemostatic imbalance in hyper-
2548–2553
54 Siegerink B, Govers-Riemslag JW, Rosendaal FR, Ten Cate H, Algra
A. Intrinsic coagulation activation and the risk of arterial throm-
boembolism in young women: results from the Risk of Arterial Throm-
boembolism in relation to Oral contraceptives (RATIO) case-control
study. Circulation 2010;122(18):1854–1861
activate factor XII in humans, leading to kallikrein formation
3208–3218
56 Lee SY, Niikura T, Iwakura T, Sakai Y, Kuroda R, Kurosaka M.
Thrombin-antithrombin III complex tests. J Orthop Surg (Hong
Kong) 2017;25(01):170840616684501
57 de Maat S, van Dooremalen S, de Groot PG, Maas C. A nanobody-
based method for tracking factor XII activation in plasma.
58 Hofman ZLM, de Maat S, Suffritti C, et al. Cleaved kininogen as a
59 Joseph K, Tholanikunnel BG, Kaplan AP. Factor XII-independent
cleavage of high-molecular-weight kininogen by prekallikrein
and inhibition by C1 inhibitor. J Allergy Clin Immunol 2009;124
(01):143–149
60 Madsen DE, Sidelmann J, Overgaard K, Koch C, Gram JB. ELISA
determination of total coagulation factor XII concentration
61 Zini JM, Schmaier AH, Cines DB. Bradykinin regulates the expres-
sion of kininogen binding sites on endothelial cells. Blood 1993;
81(11):2996–2946
system activation and bradykinin (B2) receptors in indometh-
cin induced enterocolitis in genetically susceptible Lewis rats.
63 Murphy LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-
converting enzyme insertion/deletion polymorphism modulates
the human in vivo metabolism of bradykinin. Circulation 2000;
102(08):829–832
64 Murphy LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD.
Quantification of BK1–5, the stable bradykinin plasma metabo-
lite in humans, by a highly accurate liquid-chromatographic
tandem mass spectrometric assay. Anal Biochem 2001;292
(01):87–93
65 Yu HS, Wang SW, Chang AC, et al. Bradykinin promotes vascular
endothelial growth factor expression and increases angiogenesis
in human prostate cancer cells. Biochem Pharmacol 2014;87
(02):243–253
66 Cuddapat VA, Turner KL, Seifert S, Sontheimer H. Bradykinin-
induced chemotaxis of human gliomas requires the activation
67 Pan J, Qian Y, Weiser P, et al. Glycosaminoglycans and activated
contact system in cancer patient plasmas. Prog Mol Biol Transl
Sci 2010;93:473–495
68 Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer:
small particle, big player. J Hematol Oncol 2015;8:83
69 Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and
tissue factor-bearing microparticles in cancer patients with and
without venous thromboembolism. Thromb Res 2011;127(05):
473–477
70 Sartori MT, Dell’Aquila P, Ballin A, et al. Circulating microparticles
of glial origin and tissue factor bearing in high-grade glioma:
a potential prothrombotic role. Thromb Haemost 2013;110(02):
378–385
71 Zhao L, Bi Y, Kou J, Shi J, Piao D. Phosphatidylinserine exposing-
platelets and microparticles promote procoagulant activity
35:54
72 Lechner D, Weltermann A. Chemotherapy-induced thrombosis:
a role for microparticles and tissue factor? Semin Thromb
Hemost 2008;34(02):199–203
73 Mezouar S, Mege D, Darbousset R, et al. Involvement of platelet-
derived microparticles in tumor progression and thrombosis.
Semin Oncol 2014;41(03):346–355
74 Žmigrodzka M, Guzera M, Miśkiewicz A, Jagielski D, Winnicka A.
The biology of extracellular vesicles with focus on platelet
microparticles and their role in cancer development and pro-
75 Geddings JE, Mackman N. Tumor-derived tissue factor-positive
microparticles and venous thrombosis in cancer patients. Blood
2013;122(11):1873–1880
tumor microvesicles activate platelets and enhance thrombosis
Fuchs TA, Brill A, Duerschmied D, et al. Extracellular DNA traps

Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy

Vu TT, Leslie BA, Stafford AR, Zhou J, Fredenburgh JC, Weitz JI.

Ivanov I, Shakhawat R, Sun MF, et al. Nucleic acids as cofactors for

Oehmcke S, Mörgelin M, Herwald H. Activation of the human

Gould TJ, Lysov Z, Liaw PC. Extracellular DNA and histones:

Yi Z, Liu B, Guan X, Ma F. Plasma cell-free DNA and survival in

Leal AC, Mizurini DM, Gomes T, et al. Tumor-derived exosomes

Muhsin-Sharafaldine MR, Saunderson SC, Dunn AC, Faed JM,


This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
Weitz JI, Fredenburgh JC. Factors XI and XII as targets for new anticoagulants. Thrombosis and Haemostasis Vol. 118 No. 2/2018